INBX Inhibrx Biosciences, Inc.
Healthcare$106.85+5.46%ClosedMarket Cap: $1.57B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-75.07
P/S
1143.45
EV/EBITDA
-11.36
DCF Value
$0.74
FCF Yield
-8.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-35.6%
Operating Margin
-9465.5%
Net Margin
-10014.2%
ROE
-563.9%
ROA
-70.8%
ROIC
-77.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-30.9M | $-33.4M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-30.9M | $-32.8M | $— | — |
| FY null | $1.3M | -91.0% | $-135.0M | $-140.1M | $— | — |
| Q3 null | $0.00 | NaN% | $-33.8M | $-35.3M | $— | — |
| Q2 null | $1.3M | 49.1% | $-27.4M | $-28.7M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-42.9M | $-43.3M | $— | — |
| Q4 null | $100.0K | -589.0% | $-49.9M | $-47.9M | $— | — |
| FY null | $200.0K | -1042.5% | $-331.4M | $1.69B | $— | $0.85 |
| Q3 null | $0.00 | -Infinity% | $-46.8M | $-43.9M | $— | — |
| Q2 null | $100.0K | 100.0% | $-160.9M | $1.86B | $— | $0.85 |
| Q1 null | $0.00 | -Infinity% | $-73.8M | $-78.7M | $— | — |
| Q4 2023 | $1.6M | 81.8% | $-88.3M | $-93.6M | $-1.73 | — |